Related Experiment Video
Updated: May 31, 2026
09:57
Evaluation of the In vivo Antitumor Activity of Polyanhydride IL-1α Nanoparticles
Published on: June 28, 2021
Anti-IL-1β therapies
1Women's Hospital and Department of Biomedicine, University of Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland. hzhang@uhbs.ch
Recent Patents on DNA & Gene Sequences
|July 19, 2011
Summary
Interleukin-1 beta (IL-1β) is key in inflammatory diseases and is activated by inflammasomes. Patenting inflammasome research is paving the way for novel anti-inflammatory therapies.
Area of Science:
- Immunology
- Pharmacology
- Biochemistry
Background:
- Interleukin-1 beta (IL-1β) is a major cytokine driving inflammatory diseases.
- Inflammasomes activate IL-1β upon sensing danger signals, highlighting their role in pathogenesis.
- IL-1β is a significant target for developing new anti-inflammatory drugs.
Purpose of the Study:
- To review current patent landscapes concerning IL-1β blockade strategies.
- To explore the therapeutic potential of targeting inflammasomes for inflammatory conditions.
- To forecast future patenting trends in inflammasome research and drug development.
Main Methods:
- Analysis of existing patents focusing on IL-1β inhibitors.
- Review of approved and investigational IL-1β targeting agents.
- Examination of the role of inflammasomes in disease and therapeutic intervention.
Main Results:
- Patents primarily cover methods and applications of four IL-1β blockade types: antibodies, IL-1 receptor antagonists (sIL-1Ra, icIL-1Ra), and IL-1 traps.
- Rilonacept and canakinumab are FDA-approved, with other agents showing promise in clinical trials.
- Significant patent activity exists, reflecting the therapeutic interest in IL-1β pathways.
Conclusions:
- The patent landscape indicates robust development in IL-1β targeted therapies.
- Approved and investigational drugs demonstrate the clinical viability of IL-1β blockade.
- Future patents in inflammasome research are expected to drive innovation in anti-inflammatory treatments.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms: